Special Considerations for the Treatment of Multiple Myeloma According to Advanced Age, Comorbidities, Frailty and Organ Dysfunction

Overview

Journal Crit Rev Oncol Hematol

Specialty Hematology

Date 2019 Apr 25

PMID 31014512

Citations 13

Authors

Muhammad Asad Fraz

Faiza Hassan Warraich

Sami Ullah Warraich

Muhammad Junaid Tariq

Zabih Warraich

Ali Younas Khan

Muhammad Usman

Awais Ijaz

Pavan Tenneti

Adeela Mushtaq

Faisal Akbar

Zaina Shahid

Zeeshan Ali

Hafiz Muhammad Fazeel

Cesar Rodriguez

Aboo Nasar

Ali McBride

Faiz Anwer

Affiliations

Soon will be listed here.

Abstract

Multiple Myeloma (MM) is primarily a disease of old age with a median age of sixty-nine years at diagnosis. The development of novel therapies for induction and use of autologous stem cell transplantation has resulted in improved clinical outcomes and better quality of life for MM patients. Elderly patients, comprising the majority of MM population, have a higher incidence of age-related comorbidities, frailty and organ dysfunction which complicates the coordination of treatment and limits the selection of therapies. Even in the era of multiple chemotherapeutic options, the clinical heterogeneity of the myeloma patients' demands personalized treatments which often require dose-adjustments or dose delays. The use of reduced-dose regimens and various comorbidity indices has improved clinical outcome and regimen tolerability in MM patients with renal, neurological and bone abnormalities. We focus on advancements in the treatment of multiple myeloma with the goal to guide clinicians towards patient-specific management.

Citing Articles

Trajectory, interactions, and predictors of higher symptom burden during induction therapy for multiple myeloma.

Kamal M, Shi Q, Shen S, Cleeland C, Wang X J Patient Rep Outcomes. 2024; 8(1):141.

PMID: 39630196 PMC: 11618278. DOI: 10.1186/s41687-024-00817-6.

Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM).

Batinic J, Dreta B, Rincic G, Mrdeza A, Jakobac K, Kristo D Medicina (Kaunas). 2024; 60(11).

PMID: 39597090 PMC: 11596887. DOI: 10.3390/medicina60111905.

CT-defined muscle density as a prognostic factor in multiple myeloma undergoing autologous stem cell therapy: a retrospective single center study.

Surov A, Ponisch W, Borggrefe J, Meyer H J Cancer Res Clin Oncol. 2024; 150(11):499.

PMID: 39546043 PMC: 11567988. DOI: 10.1007/s00432-024-06009-5.

Outcomes of melphalan 140 mg/m followed by autologous stem cell transplantation in multiple myeloma patients with co-morbidities: Single-centre experience.

Melotti D, Asher S, Troy-Barnes E, Nesr G, Wilson W, Camilleri M EJHaem. 2024; 5(5):1102-1106.

PMID: 39415903 PMC: 11474341. DOI: 10.1002/jha2.977.

Clinical consensus on treatments for transplant-ineligible newly diagnosed multiple myeloma: double-blinded Delphi panel.

Fonseca R, Rossi A, Medhekar R, Voelker J, Homan T, Wilcock J Future Oncol. 2024; 20(23):1645-1656.

PMID: 38861282 PMC: 11485956. DOI: 10.1080/14796694.2024.2342228.

References

Haynes R, Leung N, Kyle R, Winearls C . Myeloma kidney: improving clinical outcomes?. Adv Chronic Kidney Dis. 2012; 19(5):342-51. DOI: 10.1053/j.ackd.2012.03.001. View

Kyle R, Gertz M, Witzig T, Lust J, Lacy M, Dispenzieri A . Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78(1):21-33. DOI: 10.4065/78.1.21. View

Ozaki S, Harada T, Saitoh T, Shimazaki C, Itagaki M, Asaoku H . Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network. Acta Haematol. 2014; 132(2):211-9. DOI: 10.1159/000357394. View

Gregersen H, Juul Vangsted A, Abildgaard N, Andersen N, Schou Pedersen R, Frolund U . The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study. Cancer Med. 2017; 6(7):1807-1816. PMC: 5504337. DOI: 10.1002/cam4.1128. View

Streiff M, Holmstrom B, Ashrani A, Bockenstedt P, Chesney C, Eby C . Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. J Natl Compr Canc Netw. 2015; 13(9):1079-95. DOI: 10.6004/jnccn.2015.0133. View

Larocca A, Dold S, Zweegman S, Terpos E, Wasch R, DAgostino M . Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia. 2018; 32(8):1697-1712. DOI: 10.1038/s41375-018-0142-9. View

Ludwig H, Miguel J, Dimopoulos M, Palumbo A, Garcia Sanz R, Powles R . International Myeloma Working Group recommendations for global myeloma care. Leukemia. 2013; 28(5):981-92. DOI: 10.1038/leu.2013.293. View

Kalra S, Jain V . Dental complications and management of patients on bisphosphonate therapy: A review article. J Oral Biol Craniofac Res. 2015; 3(1):25-30. PMC: 3942225. DOI: 10.1016/j.jobcr.2012.11.001. View

Morabito F, Gentile M, Ciolli S, Petrucci M, Galimberti S, Mele G . Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol. 2009; 84(3):223-8. DOI: 10.1111/j.1600-0609.2009.01385.x. View

10.

Wu W, Merriman K, Nabaah A, Seval N, Seval D, Lin H . The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer. 2014; 111(3):628-36. PMC: 4119980. DOI: 10.1038/bjc.2014.307. View

11.

Cornell R, Goldhaber S, Engelhardt B, Moslehi J, Jagasia M, Patton D . Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy. Front Oncol. 2019; 9:45. PMC: 6401636. DOI: 10.3389/fonc.2019.00045. View

12.

Anderson K, Ismaila N, Flynn P, Halabi S, Jagannath S, Ogaily M . Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018; 36(8):812-818. DOI: 10.1200/JCO.2017.76.6402. View

13.

Benboubker L, Dimopoulos M, Dispenzieri A, Catalano J, Belch A, Cavo M . Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014; 371(10):906-17. DOI: 10.1056/NEJMoa1402551. View

14.

Bouza C, Lopez-Cuadrado T, Cediel P, Saz-Parkinson Z, Amate J . Balloon kyphoplasty in malignant spinal fractures: a systematic review and meta-analysis. BMC Palliat Care. 2009; 8:12. PMC: 2746801. DOI: 10.1186/1472-684X-8-12. View

15.

Weber D, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer E . Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007; 357(21):2133-42. DOI: 10.1056/NEJMoa070596. View

16.

Dimopoulos M, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S . Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010; 28(33):4976-84. DOI: 10.1200/JCO.2010.30.8791. View

17.

Badros A, Goloubeva O, Terpos E, Milliron T, Baer M, Streeten E . Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br J Haematol. 2008; 142(3):492-4. DOI: 10.1111/j.1365-2141.2008.07214.x. View

18.

Palumbo A, Cavallo F, Gay F, Di Raimondo F, Yehuda D, Petrucci M . Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014; 371(10):895-905. DOI: 10.1056/NEJMoa1402888. View

19.

Dimopoulos M, Richardson P, Schlag R, Khuageva N, Shpilberg O, Kastritis E . VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA.... J Clin Oncol. 2009; 27(36):6086-93. DOI: 10.1200/JCO.2009.22.2232. View

20.

Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E . European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015; 100(10):1254-66. PMC: 4591757. DOI: 10.3324/haematol.2014.117176. View